Goldstein Advisors LLC Sells 2,298 Shares of Exact Sciences Corporation $EXAS

Goldstein Advisors LLC trimmed its holdings in shares of Exact Sciences Corporation (NASDAQ:EXAS) by 18.8% during the second quarter, HoldingsChannel reports. The fund owned 9,956 shares of the medical research company’s stock after selling 2,298 shares during the quarter. Goldstein Advisors LLC’s holdings in Exact Sciences were worth $529,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in EXAS. Larson Financial Group LLC grew its holdings in Exact Sciences by 2,804.8% during the 1st quarter. Larson Financial Group LLC now owns 610 shares of the medical research company’s stock worth $26,000 after acquiring an additional 589 shares during the last quarter. National Pension Service grew its holdings in Exact Sciences by 75.1% during the 1st quarter. National Pension Service now owns 681 shares of the medical research company’s stock worth $29,000 after acquiring an additional 292 shares during the last quarter. SVB Wealth LLC bought a new stake in Exact Sciences during the 1st quarter worth approximately $30,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in Exact Sciences during the 1st quarter worth approximately $34,000. Finally, Banque Cantonale Vaudoise bought a new stake in Exact Sciences during the 1st quarter worth approximately $34,000. 88.82% of the stock is owned by institutional investors.

Exact Sciences Stock Down 0.1%

Shares of NASDAQ EXAS opened at $61.23 on Friday. The company has a market capitalization of $11.59 billion, a P/E ratio of -11.28, a price-to-earnings-growth ratio of 5.65 and a beta of 1.24. Exact Sciences Corporation has a 52-week low of $38.81 and a 52-week high of $72.83. The company has a debt-to-equity ratio of 0.94, a quick ratio of 2.56 and a current ratio of 2.89. The company’s 50 day moving average price is $52.24 and its 200-day moving average price is $51.12.

Exact Sciences (NASDAQ:EXAS) last released its earnings results on Wednesday, August 6th. The medical research company reported $0.22 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.02) by $0.24. Exact Sciences had a negative net margin of 34.19% and a negative return on equity of 1.75%. The company had revenue of $811.09 million for the quarter, compared to the consensus estimate of $774.43 million. During the same quarter in the previous year, the company earned ($0.09) EPS. Exact Sciences’s quarterly revenue was up 16.0% compared to the same quarter last year. Equities analysts forecast that Exact Sciences Corporation will post -0.58 earnings per share for the current year.

Insider Activity

In related news, Director James Edward Doyle sold 2,000 shares of the business’s stock in a transaction on Thursday, October 9th. The shares were sold at an average price of $60.00, for a total transaction of $120,000.00. Following the transaction, the director owned 57,962 shares in the company, valued at $3,477,720. The trade was a 3.34% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 1.20% of the stock is owned by insiders.

Analysts Set New Price Targets

EXAS has been the topic of a number of research reports. BTIG Research reduced their target price on shares of Exact Sciences from $65.00 to $60.00 and set a “buy” rating on the stock in a report on Tuesday, August 12th. Cowen restated a “buy” rating on shares of Exact Sciences in a research report on Thursday, August 7th. Royal Bank Of Canada dropped their price target on shares of Exact Sciences from $54.00 to $46.00 and set a “sector perform” rating on the stock in a research report on Thursday, August 7th. UBS Group dropped their price target on shares of Exact Sciences from $61.00 to $53.00 and set a “neutral” rating on the stock in a research report on Thursday, August 7th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Exact Sciences in a research report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have given a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $69.19.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.